Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells

Journal of Medicinal Chemistry

Volumn 56, Issue 2, 2013, Pages 427-436

  Marek, Linda ^a   Hamacher, Alexandra ^a   Hansen, Finn K ^a   Kuna, Krystina ^a   Gohlke, Holger ^a   Kassack, Matthias U ^a   Kurz, Thomas ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; LMK 235; N (2 HYDROXYPHENYL) 6 [(3 PHENYLUREIDO)OXY]HEXANAMIDE; N HYDROXY 5 [(3 PHENYLUREIDO)OXY]PENTANAMIDE; N HYDROXY 6 [[3 (4 TOLYL)UREIDO]OXY]HEXANAMIDE; N HYDROXY N METHYL 6 [(3 PHENYLUREIDO)OXY]HEXANAMIDE; N(2 AMINOPHENYL) 6 [(3 PHENYLUREIDO)OXY]HEXANAMIDE; N[[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY] 2 PHENYLHYDRAZINE CARBOXAMIDE; N[[6 (HYDROXYAMINO) 6 OXOHEXYL]OXY] 3,5 DIMETHYLBENZAMIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; OVARY CARCINOMA; TONGUE CANCER;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; REPRESSOR PROTEINS; SPECTROPHOTOMETRY, INFRARED;

EID: 84872823252     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301254q     Document Type: Article

References (39)

1. Biel, M.; Wascholowski, V.; Giannis, A. Epigenetics-an epicenter of gene regulation: histones and histone-modifying enzymes Angew. Chem., Int. Ed. 2005, 44, 3186-3216
2. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic J. Med. Chem. 2008, 51, 1505-1529
3. Schemies, J.; Sippl, W.; Jung, M. Histone deacetylase inhibitors that target tubulin Cancer lett. 2009, 280, 222-232
4. Bertrand, P. Inside HDAC with HDAC inhibitors Eur. J. Med. Chem. 2010, 45, 2095-2116
5. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009, 277, 8-21
6. Agis-Balboa, R. C.; Pavelka, Z.; Kerimoglu, C.; Fischer, A. Loss of HDAC5 impairs memory function: implications for Alzheimer's disease J. Alzheimer's Dis. 2013, 33, 35-44
7. Zhang, H.; Xiao, Y.; Zhu, Z.; Li, B.; Greene, M. I. Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity Immunol. Cell. Biol. 2012, 90, 95-100
8. Khan, O.; La Thangue, N. B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications Immunol. Cell Biol. 2012, 90, 85-94
9. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors J. Med. Chem. 2003, 46, 5097-5116
10. Schlimme, S.; Hauser, A.-T.; Carafa, V.; Heinke, R.; Kannan, S.; Stolfa, D. A.; Cellamare, S.; Carotti, A.; Altucci, L.; Jung, M.; Sippl, W. Carbamate prodrug concept for hydroxamate HDAC inhibitors ChemMedChem 2011, 6, 1193-1198
11. Schäfer, S.; Saunders, L.; Schlimme, S.; Valkov, V.; Wagner, J. M.; Kratz, F.; Sippl, W.; Verdin, E.; Jung, M. Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors ChemMedChem 2009, 4, 283-290
12. Stolfa, D. A; Stefanachi, A.; Gajer, J. M.; Nebbioso, A.; Altucci, L.; Cellamare, S.; Jung, M.; Carotti, A. Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors ChemMedChem 2012, 7, 1256-1266
13. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999, 401, 188-193
14. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkühler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 15064-15069
15. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfí, A.; De Francesco, R.; Steinkühler, C.; Di Marco, S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex EMBO Rep. 2007, 8, 879-884
16. Balasubramanian, S.; Verner, E.; Buggy, J. J. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett. 2009, 280, 211-221
17. Thurn, K. T.; Thomas, S.; Moore, A.; Munster, P. N. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer Future Oncol. 2011, 7, 263-283
18. Noureen, N.; Rashid, H.; Kalsoom, S. Identification of type-specific anticancer histone deacetylase inhibitors: road to success Cancer Chemother. Pharmacol. 2010, 66, 625-633
19. Bieliauskas, A. V.; Pflum, M. K. H. Isoform-selective histone deacetylase inhibitors Chem. Soc. Rev. 2008, 37, 1402-1413
20. Bots, M.; Johnstone, R. W. Rational combinations using HDAC inhibitors Clin. Cancer Res. 2009, 15, 3970-3977
21. Ong, P.-S.; Wang, X.-Q.; Lin, H.-S.; Chan, S.-Y.; Ho, P. C. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells Int. J. Oncol. 2012, 40, 1705-1713
22. Morris, G.; Goodsell, D. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662
23. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions J. Mol. Biol. 2000, 295, 337-356
24. Sotriffer, C. A.; Gohlke, H.; Klebe, G. Docking into knowledge-based potential fields: a comparative evaluation of DrugScore J. Med. Chem. 2002, 45, 1967-1970
25. Bottomley, M. J.; Lo Surdo, P.; Di Giovine, P.; Cirillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkühler, C.; Gallinari, P.; Carfí, A. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain J. Biol. Chem. 2008, 283, 26694-26704
26. Oger, F.; Lecorgne, A.; Sala, E.; Nardese, V.; Demay, F.; Chevance, S.; Desravines, D. C.; Aleksandrova, N.; Le Guével, R.; Lorenzi, S.; Beccari, A. R.; Barath, P.; Hart, D. J.; Bondon, A.; Carettoni, D.; Simonneaux, G.; Salbert, G. Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring J. Med. Chem. 2010, 53, 1937-1950
27. Brunsteiner, M.; Petukhov, P. A. Insights from comprehensive multiple receptor docking to HDAC8 J. Mol. Model. 2012, 18, 3927-3939
28. Kazemi, S.; Krüger, D. M.; Sirockin, F.; Gohlke, H. Elastic potential grids: accurate and efficient representation of intermolecular interactions for fully flexible docking ChemMedChem 2009, 4, 1264-1268
29. Stronach, E. A.; Alfraidi, A.; Rama, N.; Datler, C.; Studd, J.; Agarwal, R.; Guney, T. G.; Gourley, C.; Hennessy, B. T.; Mills, G. B.; Mai, A.; Brown, R.; Dina, R.; Gabra, H. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer Cancer Res. 2011, 71, 4412-4422
30. Hager, K.; Franz, A.; Hirsch, A. Self-assembly of chiral depsipeptide dendrimers Chem.-Eur. J. 2006, 12, 2663-2679
31. Li, J.; Yao, S. Q. "Singapore Green": a new fluorescent dye for microarray and bioimaging applications Org. Lett. 2009, 11, 405-408
32. Gediya, L. K.; Chopra, P.; Purushottamachar, P.; Maheshwari, N.; Njar, V. C. O. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells J. Med. Chem. 2005, 48, 5047-5051
33. Gosepath, E. M.; Eckstein, N.; Hamacher, A.; Servan, K.; von Jonquieres, G.; Lage, H.; Györffy, B.; Royer, H. D.; Kassack, M. U. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1 Int. J. Cancer 2008, 123, 2013-2019
34. Eckstein, N.; Servan, K.; Girard, L.; Cai, D.; von Jonquieres, G.; Jaehde, U.; Kassack, M. U.; Gazdar, A. F.; Minna, J. D.; Royer, H. D. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells J. Biol. Chem. 2008, 283, 739-750
35. Mueller, H.; Kassack, M. U.; Wiese, M. Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines J. Biomol. Screening 2004, 9, 506-515
36. Ciossek, T.; Julius, H.; Wieland, H.; Maier, T.; Beckers, T. A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening Anal. Biochem. 2008, 372, 72-81
37. Bonfils, C.; Kalita, A.; Dubay, M.; Siu, L. L.; Carducci, M. A.; Reid, G.; Martell, R. E.; Besterman, J. M.; Li, Z. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay Clin. Cancer Res. 2008, 14, 3441-3449
38. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 2010, 70, 440-446
39. Gerber, P. R.; Müller, K. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry J. Comput.-Aided Mol. Des. 1995, 9, 251-268